Although Pitteri et al. reported that CSF CXCL-13 levels were able to differentiate the degree of CI severity in a population of CIS, RRMS and PPMS patients, only three subjects of the latter subtype were included [90]. This evidence concerns the gene CXCL13 and in situ carcinoma.